(Q44179156)

30 November 2017

title

A novel model for evaluating the risk of hepatitis B recurrence after liver transplantation (English)

1 reference

30 November 2017

main subject

liver transplantation

1 reference

Xiao Xu

1

1 reference

30 November 2017

Zhenhua Tu

2

1 reference

30 November 2017

Bei Wang

3

1 reference

30 November 2017

Qi Ling

4

1 reference

30 November 2017

Lin Zhang

5

1 reference

30 November 2017

Lin Zhou

6

1 reference

30 November 2017

Guoping Jiang

7

1 reference

30 November 2017

Jian Wu

8

1 reference

30 November 2017

Shusen Zheng

9

1 reference

30 November 2017

language of work or name

1 reference

29 March 2011

1 reference

30 November 2017

1 reference

30 November 2017

volume

31

1 reference

30 November 2017

issue

10

1 reference

30 November 2017

page(s)

1477-1484

1 reference

Hepatitis viruses and liver transplantation.

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

In vitro infection of human peripheral blood mononuclear cells by a defective hepatitis B virus with a deletion in the PreS1 region of the viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Liver transplantation for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Management of hepatitis B in liver transplantation patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Prophylaxis and treatment of recurrent hepatitis B after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Evolving experience of hepatitis B virus prophylaxis in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Evolving strategies to prevent HBV recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Current pharmacotherapy for the treatment of chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Adult-to-adult transplantation of the right hepatic lobe from a living donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02500.X

10.1111/J.1478-3231.2011.02500.X

21 January 2018

Identifiers

DOI

1 reference

30 November 2017

1 reference